Brandon Roth, MD
Interventional Pain Medicine · Glendale, AZNPI 1568849990
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Nalu Medical, Inc. at 31.7% of the total. Reporting peaked in 2021 at $10,673 and has fallen 84.0% since, to $1,707 in 2025.
Across 319 payments — averaging $89.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nalu Medical, Inc.$9K
- Omnia Medical, LLC$5K
- Abbott$4K
- Nevro Corp.$3K
- Boston Scientific$3K
- Vertos Medical, Inc.$1K
- plus $3K from 28 others
Across 29 payments — averaging $1251.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$36K
What the payments were for
- Consulting fees$11,75641%
- Grants$750%
- Travel & lodging$2,4499%
- Food & beverage$14,28050%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nalu Medical, Inc. | 45 | $9,095 |
| Omnia Medical, LLC | 3 | $4,831 |
| Abbott | 80 | $4,330 |
| Nevro Corp. | 65 | $3,327 |
| Boston Scientific | 30 | $2,559 |
| Vertos Medical, Inc. | 18 | $1,097 |
| Medtronic(2 entities) | 20 | $801 |
| Globus Medical(2 entities) | 7 | $668 |
| Axonics, Inc. | 8 | $404 |
| SPR Therapeutics, Inc | 4 | $315 |
| Camber Spine Technologies LLC | 1 | $189 |
| Stryker | 3 | $180 |
| Biotronik NRO, Inc. | 1 | $147 |
| Relievant Medsystems, Inc. | 1 | $137 |
| Collegium Pharmaceutical, Inc. | 8 | $128 |
| Hikma Pharmaceuticals USA | 4 | $68 |
| Painteq LLC | 2 | $55 |
| Scilex Pharmaceuticals Inc. | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Amgen | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $25 |
| Valinor Pharma, LLC | 1 | $23 |
| AbbVie | 1 | $20 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| Bioventus LLC | 1 | $19 |
| Otto Bock Healthcare LP | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Electronic Waveform Lab, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Foundation Fusion Solutions, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nalu Neurostimulation System$8,080
- PROCLAIM$1,638
- Senza Spinal Cord Stimulation System$1,592
- Intracept$1,143
- mild Device Kit$1,019
- Proclaim IPG$524
- ETERNA$421
- XLIF$331
- Modulus$279
- Axonics$249
- SUPERION$233
- INTELLIS ADAPTIVESTIM$154
- Prospera$147
- WaveWriter Alpha Prime 16$141
- Octrode SCS Leads$140
- SPRINT PNS System$131
- CLICK$119
- OCTRODE$115
- Proclaim Family of SCS IPGs$112
- SPECTRA WAVEWRITER$110
How this compares
$28,687 in reported general payments places this provider in the 85th percentile of 64 interventional pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 32 | $20,427 |
| LinzessLinaclotide | 12 | $9,485 |
| Buprenorphine | 46 | $9,055 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 449 | $9,015 |
| Pregabalin | 283 | $6,497 |
| Xtampza ErOxycodone Myristate | 15 | $5,214 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 224 | $4,958 |
| Fentanyl | 11 | $4,037 |
| Celecoxib | 122 | $3,888 |
| Gabapentin | 203 | $3,552 |
| Oxycodone Hcl | 201 | $2,857 |
| Hydromorphone ErHydromorphone Hcl | 17 | $2,636 |
| Tizanidine Hcl | 124 | $2,042 |
| Morphine Sulfate ErMorphine Sulfate | 67 | $1,850 |
| Duloxetine Hcl | 85 | $1,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $128 | $25,64147 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $68 | $10,18089 claims |
| AbbVieLinzess | $20 | $9,48512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 interventional pain medicine providers in Arizona.
Other interventional pain medicine in Glendale
- Vikramjeet SainiGlendale$21K
- Sean OrmondGlendale$11K
- Paul LynchScottsdale$283K
- Jack DiepLake Havasu City$233K
- Matthew RansonMesa$86K
- Steven SiwekPhoenix$57K
- Ajay YedduGilbert$52K
- Ramoun JonesPhoenix$51K
- Lisa StearnsPhoenix$48K
- Sachin NarainGilbert$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.